Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Impact of advanced age on survival in patients with implantable cardioverter defibrillators.

Pellegrini CN, Lee K, Olgin JE, Turakhia MP, Tseng ZH, Lee R, Badhwar N, Lee B, Varosy PD.

Europace. 2008 Nov;10(11):1296-301. doi: 10.1093/europace/eun253. Epub 2008 Sep 24.

2.

Impact of renal function on survival in patients with implantable cardioverter-defibrillators.

Turakhia MP, Varosy PD, Lee K, Tseng ZH, Lee R, Badhwar N, Scheinman M, Lee BK, Olgin JE.

Pacing Clin Electrophysiol. 2007 Mar;30(3):377-84.

PMID:
17367357
3.

Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.

Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G.

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306. Epub 2015 Feb 10.

4.

Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit.

Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J.

Circ Arrhythm Electrophysiol. 2012 Aug 1;5(4):706-13. doi: 10.1161/CIRCEP.112.970798. Epub 2012 Jun 8.

5.

Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis.

Nakhoul GN, Schold JD, Arrigain S, Harb SC, Jolly S, Wilkoff BL, Nally JV Jr, Navaneethan SD.

Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1119-27. doi: 10.2215/CJN.11121114. Epub 2015 Jun 25.

6.

The gender-paradox among patients with implantable cardioverter-defibrillators: a propensity-matched study.

Bhavnani SP, Pavuluri V, Coleman CI, Guertin D, Yarlagadda RK, Clyne CA, Kluger J.

Pacing Clin Electrophysiol. 2013 Jul;36(7):878-84. doi: 10.1111/pace.12141. Epub 2013 Apr 24.

PMID:
23614760
7.

Survival and appropriate device interventions in recipients of cardioverter defibrillators implanted for the primary versus secondary prevention of sudden cardiac death.

Stockburger M, Krebs A, Nitardy A, Habedank D, Celebi O, Knaus T, Dietz R.

Pacing Clin Electrophysiol. 2009 Mar;32 Suppl 1:S16-20. doi: 10.1111/j.1540-8159.2008.02222.x.

PMID:
19250084
8.

Long-term follow-up of patients supplied with single-chamber or dual-chamber cardioverter defibrillators.

Kolb C, Deisenhofer I, Schmieder S, Barthel P, Zrenner B, Karch MR, Schmitt C.

Pacing Clin Electrophysiol. 2006 Sep;29(9):946-52.

PMID:
16981917
9.

Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).

Ruwald AC, Schuger C, Moss AJ, Kutyifa V, Olshansky B, Greenberg H, Cannom DS, Estes NA, Ruwald MH, Huang DT, Klein H, McNitt S, Beck CA, Goldstein R, Brown MW, Kautzner J, Shoda M, Wilber D, Zareba W, Daubert JP.

Circ Arrhythm Electrophysiol. 2014 Oct;7(5):785-92. doi: 10.1161/CIRCEP.114.001623. Epub 2014 Aug 18.

10.

The association between ICD interventions and mortality is independent of their modality: clinical implications.

Bencardino G, Di Monaco A, Rio T, Frontera A, Santangeli P, Leo M, Pelargonio G, Perna F, Narducci ML, Gabrielli F, Lanza GA, Bellocci F, Rebuzzi A, Crea F.

J Cardiovasc Electrophysiol. 2014 Dec;25(12):1363-7. doi: 10.1111/jce.12499. Epub 2014 Sep 3.

PMID:
25066621
11.

The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.

Chen HA, Hsia HH, Vagelos R, Fowler M, Wang P, Al-Ahmad A.

Pacing Clin Electrophysiol. 2007 Mar;30(3):390-4.

PMID:
17367359
12.

Poor prognosis for patients with chronic kidney disease despite ICD therapy for the primary prevention of sudden death.

Cuculich PS, Sánchez JM, Kerzner R, Greenberg SL, Sengupta J, Chen J, Faddis MN, Gleva MJ, Smith TW, Lindsay BD.

Pacing Clin Electrophysiol. 2007 Feb;30(2):207-13.

PMID:
17338717
13.

Primary prevention implantation of cardioverter defibrillator without defibrillation threshold testing: 2-year follow-up.

Bianchi S, Ricci RP, Biscione F, Sgreccia F, Di Belardino N, Rossi P, Giuli S, Grammatico A, De Santo T, Santi E, Merico M, Piccirillo G, Azzolini P, Santini M, Puglisi A.

Pacing Clin Electrophysiol. 2009 May;32(5):573-8. doi: 10.1111/j.1540-8159.2009.02329.x.

PMID:
19422577
14.

Arrhythmic death in implantable cardioverter defibrillator patients: a long-term study over a 10 year implantation period.

Duray GZ, Schmitt J, Richter S, Israel CW, Hohnloser SH.

Europace. 2009 Nov;11(11):1462-8. doi: 10.1093/europace/eup246. Epub 2009 Sep 29.

PMID:
19797255
15.

Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention.

Khazanie P, Hellkamp AS, Fonarow GC, Bhatt DL, Masoudi FA, Anstrom KJ, Heidenreich PA, Yancy CW, Curtis LH, Hernandez AF, Peterson ED, Al-Khatib SM.

J Am Heart Assoc. 2015 Aug 6;4(8):e002061. doi: 10.1161/JAHA.115.002061.

16.

Predictors of early mortality in implantable cardioverter-defibrillator recipients.

Stein KM, Mittal S, Gilliam FR, Gilligan DM, Zhong Q, Kraus SM, Meyer TE.

Europace. 2009 Jun;11(6):734-40. doi: 10.1093/europace/eup055. Epub 2009 Mar 11.

17.

Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.

Barbosa MP, da Costa Rocha MO, de Oliveira AB, Lombardi F, Ribeiro AL.

Europace. 2013 Jul;15(7):957-62. doi: 10.1093/europace/eut011. Epub 2013 Feb 1. Erratum in: Europace. 2013 Nov;15(11):1684.

PMID:
23376978
18.

Heart rate turbulence predicts ICD-resistant mortality in ischaemic heart disease.

Marynissen T, Floré V, Heidbuchel H, Nuyens D, Ector J, Willems R.

Europace. 2014 Jul;16(7):1069-77. doi: 10.1093/europace/eut303. Epub 2013 Nov 6.

PMID:
24196450
19.

Effect of age on survival and causes of death after primary prevention implantable cardioverter-defibrillator implantation.

Fauchier L, Marijon E, Defaye P, Piot O, Sadoul N, Perier MC, Gras D, Klug D, Algalarrondo V, Bordachar P, Deharo JC, Leclercq C, Babuty D, Boveda S; DAI-PP Investigators.

Am J Cardiol. 2015 May 15;115(10):1415-22. doi: 10.1016/j.amjcard.2015.02.031. Epub 2015 Feb 18.

PMID:
25784518
20.

The Neutrophil-to-Lymphocyte Ratio Predicts All-Cause Mortality in Patients with Implantable Cardioverter Defibrillators.

Hashimoto N, Arimoto T, Narumi T, Iwayama T, Kutsuzawa D, Ishigaki D, Kumagai YU, Tamura H, Nishiyama S, Takahashi H, Shishido T, Miyamoto T, Watanabe T, Kubota I.

Pacing Clin Electrophysiol. 2017 Feb;40(2):135-144. doi: 10.1111/pace.13003. Epub 2017 Jan 18.

PMID:
27996101

Supplemental Content

Support Center